Iovance Biotherapeutics (IOVA) has seen strong sales growth, particularly from its advanced melanoma treatment, Amtagvi, which earned $263.5 million last year, a 61% increase from the previous year. The company anticipates potential label expansions, including a recent promising clinical trial for advanced soft-tissue sarcomas, which could further boost sales. However, investing in Iovance carries significant risks, including potential clinical setbacks and the complexities involved in manufacturing its therapies. Given these factors, while the stock could yield high returns, investors are advised to approach with caution and consider starting with a small position.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.fool.com/investing/2026/04/10/is-this-biotech-stock-the-best-chance-to-make-a-fo/
